Figure 4.
Clinical course. The patient received 8 cycles of ritsuximab therapy, 6 cycles of CHOP therapy, and 3 cycles of prophylactic I.T. chemotherapy. He has maintained a state of CR for about 14 months. Hb, hemoglobin; sIL-2R, soluble interleukin-2 receptor.